When Should a Medical Device Company Start Using a Quality Management System?

One of the most common mistakes we see in medical device development is not that companies fail to build a Quality Management System (QMS) — it’s that they start using it too late.

Many companies begin developing their QMS only when they are approaching a regulatory submission. By that point, critical development activities have already occurred outside the system, resulting in missing documentation, incomplete design history records, inconsistent risk management files, and gaps in verification and validation evidence.

The result? Delays, remediation work, additional testing, and in some cases, regulatory rejection.

The reality is simple: If you plan to submit a medical device in the US, EU, UK, Canada, or globally, your QMS should be active long before your submission is assembled.

The Biggest Misunderstanding About QMS Implementation

A surprising number of startups and even experienced manufacturers believe a QMS is something you “turn on” near commercialization.

But regulators do not simply evaluate your final documents — they evaluate how those documents were created, controlled, reviewed, approved, and maintained throughout development.

A submission-ready device requires submission-ready quality records.

That means your:

• Design inputs
• Design outputs
• Risk management activities
• Software development records
• Verification and validation activities
• Supplier controls
• Cybersecurity documentation
• Usability engineering
• Clinical activities

…should all be generated and controlled within your QMS as they happen.

Trying to recreate this history retroactively is extremely difficult and often obvious to regulators and auditors.

The Right Time to Start Using a QMS

The best time to begin operating under a QMS is:

As soon as formal product development begins.

Not after prototype completion.
Not before submission testing.
Not during the FDA submission process.

At the beginning.

Once a company starts making design decisions, documenting requirements, developing software, generating risk analyses, or performing testing, the QMS should already be in use.

…the agency increasingly expects clear traceability between design controls, risk management, software validation, cybersecurity activities, usability engineering, and verification/validation testing.

Even if FDA does not always inspect prior to clearance, deficiencies in design controls and quality documentation can create major problems later during inspections.

For software and AI-enabled devices especially, regulators are expecting mature development controls much earlier in the lifecycle.

Companies attempting to assemble documentation late in development often discover they are missing critical evidence required for Technical Documentation reviews.

A reactive QMS approach creates the same problems seen in EU and FDA submissions.

What Happens When Companies Wait Too Long?

At RQMIS, we frequently work with companies that:

• Built excellent technology
• Conducted meaningful testing
• Created large amounts of technical documentation

…but did not operate within a functioning QMS during development.

Common consequences include:

• Rewriting development documents
• Reconstructing design history files
• Repeating verification testing
• Reworking software documentation
• Updating risk management activities
• Delaying submissions by months
• Increased consulting and remediation costs

In some cases, companies spend more fixing documentation gaps than they would have spent implementing a practical QMS early.

A QMS Should Support Development — Not Slow It Down

Another misconception is that quality systems slow innovation.

A properly designed QMS should do the opposite:

• Improve development efficiency
• Clarify responsibilities
• Reduce rework
• Improve traceability
• Simplify submissions
• Support faster scaling
• Reduce regulatory risk

The key is implementing a right-sized QMS appropriate for the company’s stage, technology, and regulatory pathway.

A startup developing an early-stage prototype does not need the same operational complexity as a multinational manufacturer — but both still need controlled development processes.

Software, AI, and Cybersecurity Raise the Stakes

The importance of early QMS implementation becomes even greater for:

• Software as a Medical Device (SaMD)
• AI/ML-enabled devices
• Connected medical devices
• Mobile health applications
• Cloud-based platforms

These technologies require:

• Software lifecycle controls
• Cybersecurity risk management
• Software verification and validation
• Configuration management
• Traceability matrices
• Human factors integration

Trying to retrofit these controls near submission is often extremely painful.

Practical Advice for Medical Device Companies

If your company is beginning product development, ask yourself:

• Are design decisions being formally documented?
• Is risk management active today?
• Are software changes controlled?
• Are verification activities traceable to requirements?
• Are cybersecurity activities documented?
• Are suppliers qualified and documented?
• Are design reviews occurring formally?

If the answer is “not yet,” your QMS likely needs to begin now — not later.

Final Thoughts

Regulatory submissions are not built in the final few months before filing.

Successful submissions are built throughout the entire product development lifecycle.

A Quality Management System is not just a regulatory requirement — it is the operational framework that creates the evidence regulators expect to see.

The earlier companies begin using their QMS correctly, the smoother their path toward FDA clearance, CE marking, UKCA approval, Health Canada licensing, and global commercialization becomes.

At RQMIS, we help companies implement practical, scalable quality systems that support both innovation and regulatory readiness from the earliest stages of development through global commercialization.